Clinical Trial Update: Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease [Phase 1]

View source ↗

Summary

A Phase 1 safety study of AADvac1, a tau peptide-KLH-conjugate active vaccine, for Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AADvac1

Snippet

Sponsor: Axon Neuroscience SE | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED